Cellebrite Plunges 31% to 52-Week Low After Slashing FY26 Guidance
CLBT is trading near its 52-week low of $9.58 (8.7% above the low) on elevated volume (11× avg).
Summary
Cellebrite shares are down 31% to $10.46, hitting a new 52-week low, after the company cut full-year 2026 revenue guidance to $555M-$561M from $565M-$571M and guided Q3 revenue below consensus. Q2 revenue of $131.14M missed estimates by $0.73M despite 15.8% YoY growth, while adjusted EPS of 11 cents met expectations. New CEO Shiven Ramji took direct responsibility, citing procurement delays with U.S. federal and European government customers. This follows the 6-K filed earlier today that announced Ramji's appointment and the guidance reduction. The magnitude of the guidance cut and the sharp selloff suggest the market is repricing the company's growth trajectory.
At the time of this announcement, CLBT was trading at $10.41 on NASDAQ in the Technology sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $9.58 to $19.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.